Alto Neuroscience, Inc. (NYSE:ANRO Get Free Report) has been given a consensus recommendation of Buy by the six research firms that are currently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued a report on the stock in the last year is $35.00.

Several equities research analysts have weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Alto Neuroscience in a research report on Friday, June 21st. They issued a buy rating and a $43.00 price objective for the company. Stifel Nicolaus restated a buy rating and issued a $32.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 25th. Finally, William Blair restated an outperform rating on shares of Alto Neuroscience in a research report on Wednesday, June 12th.

Get Our Latest Stock Report on Alto Neuroscience

Large investors have recently modified their holdings of the stock. University of Texas Texas AM Investment Managment Co. bought a new position in Alto Neuroscience during the first quarter worth about $340,000. Zimmer Partners LP bought a new position in Alto Neuroscience during the first quarter worth about $1,151,000. AWM Investment Company Inc. bought a new position in Alto Neuroscience during the first quarter worth about $4,592,000. Artal Group S.A. bought a new position in Alto Neuroscience during the first quarter worth about $5,372,000. Finally, Jennison Associates LLC bought a new position in Alto Neuroscience during the first quarter worth about $7,039,000.

NYSE ANRO opened at $14.50 on Tuesday. The company has a quick ratio of 26.02, a current ratio of 26.02 and a debt-to-equity ratio of 0.05. The businesss fifty day moving average price is $12.21. Alto Neuroscience has a 1 year low of $9.40 and a 1 year high of $24.00.

Alto Neuroscience (NYSE:ANRO Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.76) earnings per share for the quarter, missing analysts consensus estimates of ($0.46) by ($0.30). On average, sell-side analysts expect that Alto Neuroscience will post -2.93 earnings per share for the current fiscal year.

(Get Free Report

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.

Here is the original post:
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of Buy from Analysts - Defense World